Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8533943 | 0.83 | PTGES2 (0.44) | PTGES2DAOCYP3A4CYP2D6SLC6A2 | |
| SCHEMBL10325728 | 0.81 | IDO1 (0.46) | PTGES2CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL8533229 | 0.75 | GLO1 (0.62) | RIPK1GLO1DAOKDM4EDRD2 | |
| SCHEMBL14292147 | 0.70 | CDC25B (0.57) | RIPK1DAOKDM4EDRD2DRD4 | |
| SCHEMBL24103159 | 0.67 | DAO (0.50) | RIPK1DAOMAPT | |
| SCHEMBL17413481 | 0.66 | DRD2 (0.45) | RIPK1DAODRD2DRD4DRD3 | |
| SCHEMBL6988614 | 0.66 | MET (0.49) | RIPK1GLO1DAOSLC40A1 | |
| SCHEMBL4734771 | 0.66 | DRD2 (0.47) | RIPK1DAODRD2DRD4DRD3 | |
| SCHEMBL2113619 | 0.66 | DRD2 (0.53) | RIPK1DAODRD2DRD4DRD3 | |
| SCHEMBL3492565 | 0.65 | DRD2 (0.58) | RIPK1GLO1DAODRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593108-B2 | Compounds and methods for antiviral treatment | PTC THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20120135999-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135999-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | EIF2AK2, MAVS, ZC3HAV1 | PTGES2 2477/4885RIPK1 1670/4885GLO1 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.